YDESW
YD Bio Limited
Price Chart
Latest Quote
$0.46
+0.00 (+0.00%)
Current Price
| Previous Close | $0.46 |
| Open | $0.45 |
| Day High | $0.46 |
| Day Low | $0.46 |
| Volume | 6 |
Stock Information
| Total Debt | $5K |
| Cash Equivalents | $2.66M |
| Revenue | $1.24M |
| Net Income | $306K |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Sales | $1.24M |
| Income | $306K |
| Book/sh | $0.06 |
| Employees | 13 |
Financial Ratios
| Quick Ratio | 2.70 |
| Current Ratio | 5.23 |
| Debt/Eq | 0.11 |
Returns & Margins
| Gross Margin | 29.60% |
| Operating Margin | -382.12% |
| Profit Margin | 24.67% |
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
| P/B | 7.30 |
Analyst Data
| Recommendation | none |
Technical Indicators
| Shares Float | 16.19M |
| Volatility | -0.16 |
Performance History
| YTD | +0.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-23 | $0.46 | 6 |
About YD Bio Limited
YD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. The company offers eye disease treatment products, 3D LensMate Artificial Tears, a natural tear-mimicking lubricant that moisturizes the eyes and relieves dry eye symptoms; 3D LensMate Eye Drops, an ophthalmic solution to alleviate symptoms of dry eye syndrome, including irritation, foreign body sensation, and eye fatigue; and LSC Eye Drug/Injection, an injectable ophthalmic drug is being developed for the treatment of various retinal and macular disorders, such as age-related macular degeneration, macular edema, choroidal and subretinal neovascularization, and neovascular glaucoma. It also provides Hydrogel (Hioxifilcon A) Soft (Hydrophilic) Contact Lens, a spherical and aspherical lenses. In addition, the company supplies drugs and medical materials for clinical trials; and operates DNA methylation-based oncology testing programs. Further, it provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination, and compliance-focused support for clinical development programs to pharmaceutical and biotechnology companies. It serves corporate and retail customers. The company was founded in 2013 and is based in Taipei, Taiwan.
đ° Latest News
No news articles available at the moment. Check back later for updates on YDESW.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | |||
| Reconciled Cost Of Revenue | $236,093 | $260,468 | $196,686 |
| Cost Of Revenue | $429,407 | $355,004 | $196,686 |
| Total Revenue | $596,817 | $510,360 | $350,131 |
| Operating Revenue | $596,817 | $510,360 | $350,131 |
| Expenses | |||
| Interest Expense | $0 | $772 | $2,144 |
| Total Expenses | $5,865,135 | $1,972,783 | $357,247 |
| Other Income Expense | $-3,124,691 | $64,908 | $26,620 |
| Other Non Operating Income Expenses | $46,803 | $64,415 | $29,351 |
| Net Non Operating Interest Income Expense | $80,162 | $11,036 | $-1,854 |
| Interest Expense Non Operating | $0 | $772 | $2,144 |
| Operating Expense | $5,435,728 | $1,617,779 | $160,561 |
| Selling And Marketing Expense | $170,523 | $1,957 | $7,492 |
| General And Administrative Expense | $3,646,895 | $1,114,270 | $153,069 |
| Income & Earnings | |||
| Net Income From Continuing Operation Net Minority Interest | $-8,311,316 | $-1,411,559 | $13,560 |
| Net Interest Income | $80,162 | $11,036 | $-1,854 |
| Interest Income | $80,162 | $11,808 | $290 |
| Normalized Income | $-5,142,359 | $-1,411,953 | $15,658 |
| Net Income From Continuing And Discontinued Operation | $-8,311,316 | $-1,411,559 | $13,560 |
| Total Operating Income As Reported | $-5,271,721 | $-1,461,930 | $-9,847 |
| Net Income Common Stockholders | $-8,311,316 | $-1,411,559 | $13,560 |
| Net Income | $-8,311,316 | $-1,411,559 | $13,560 |
| Net Income Including Noncontrolling Interests | $-8,311,316 | $-1,411,559 | $13,560 |
| Net Income Continuous Operations | $-8,311,316 | $-1,411,559 | $13,560 |
| Pretax Income | $-8,312,847 | $-1,386,479 | $17,650 |
| Special Income Charges | $-3,403 | $493 | $-2,731 |
| Interest Income Non Operating | $80,162 | $11,808 | $290 |
| Operating Income | $-5,268,318 | $-1,462,423 | $-7,116 |
| Depreciation Amortization Depletion Income Statement | $16,246 | $10,199 | - |
| Depreciation And Amortization In Income Statement | $16,246 | $10,199 | - |
| Depreciation Income Statement | $16,246 | $10,199 | - |
| Gross Profit | $167,410 | $155,356 | $153,445 |
| Other | |||
| Tax Effect Of Unusual Items | $-2,537 | $99 | $-633 |
| Tax Rate For Calcs | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-4,931,793 | $-1,281,465 | $24,977 |
| Total Unusual Items | $-3,171,494 | $493 | $-2,731 |
| Total Unusual Items Excluding Goodwill | $-3,171,494 | $493 | $-2,731 |
| Reconciled Depreciation | $209,560 | $104,735 | $2,452 |
| EBITDA (Bullshit earnings) | $-8,103,287 | $-1,280,972 | $22,246 |
| EBIT | $-8,312,847 | $-1,385,707 | $19,794 |
| Diluted NI Availto Com Stockholders | $-8,311,316 | $-1,411,559 | $13,560 |
| Tax Provision | $-1,531 | $25,080 | $4,090 |
| Write Off | $3,403 | $-493 | $2,731 |
| Gain On Sale Of Security | $-3,168,091 | - | - |
| Research And Development | $1,602,064 | $491,353 | $0 |
| Selling General And Administration | $3,817,418 | $1,116,227 | $160,561 |
| Other Gand A | $3,646,895 | $1,114,270 | $153,069 |
Fetched: 2026-10-21
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Assets | |||
| Net Tangible Assets | $-5,465,402 | $3,910,211 | $22,994 |
| Total Assets | $13,779,397 | $6,864,226 | $321,212 |
| Total Non Current Assets | $4,109,207 | $3,396,344 | $49,488 |
| Non Current Prepaid Assets | $1,431,658 | $0 | - |
| Non Current Deferred Assets | $0 | $628,232 | $24,565 |
| Goodwill And Other Intangible Assets | $2,609,739 | $2,680,035 | $0 |
| Other Intangible Assets | $2,609,739 | $2,680,035 | - |
| Current Assets | $9,670,190 | $3,467,882 | $271,724 |
| Prepaid Assets | $1,070,770 | $35,453 | $16,788 |
| Inventory | $1,879,542 | $37,335 | $69,404 |
| Receivables | $712,263 | $262,796 | $98,434 |
| Taxes Receivable | $253,246 | $159,287 | $267 |
| Accounts Receivable | $167,477 | $86,582 | $98,167 |
| Allowance For Doubtful Accounts Receivable | $-6,598 | $-3,055 | $-3,769 |
| Gross Accounts Receivable | $174,075 | $89,637 | $101,936 |
| Cash Cash Equivalents And Short Term Investments | $6,007,615 | $3,132,298 | $87,098 |
| Cash And Cash Equivalents | $6,007,615 | $3,132,298 | $87,098 |
| Non Current Deferred Taxes Assets | - | $0 | $24,565 |
| Investmentin Financial Assets | - | $0 | $10,618 |
| Notes Receivable | - | $16,927 | $0 |
| Debt | |||
| Total Debt | $6,764 | $22,265 | $47,576 |
| Long Term Debt And Capital Lease Obligation | $0 | $5,684 | $0 |
| Current Debt And Capital Lease Obligation | $6,764 | $16,581 | $47,576 |
| Current Debt | - | $290 | $34,319 |
| Other Current Borrowings | - | - | $34,319 |
| Liabilities | |||
| Total Liabilities Net Minority Interest | $16,635,060 | $273,980 | $298,218 |
| Total Non Current Liabilities Net Minority Interest | $14,991,482 | $10,920 | $0 |
| Derivative Product Liabilities | $14,991,482 | $0 | - |
| Non Current Deferred Liabilities | $0 | $1,463 | - |
| Non Current Deferred Taxes Liabilities | $0 | $1,463 | - |
| Current Liabilities | $1,643,578 | $263,060 | $298,218 |
| Current Deferred Liabilities | $30,153 | - | $344 |
| Payables And Accrued Expenses | $1,606,661 | $246,479 | $250,298 |
| Payables | $1,203,216 | $64,119 | $237,196 |
| Other Payable | $4,261 | - | - |
| Accounts Payable | $413,290 | $26,866 | $17,976 |
| Other Non Current Liabilities | - | $3,773 | - |
| Current Notes Payable | - | $290 | $0 |
| Total Tax Payable | - | - | $1,969 |
| Equity | |||
| Common Stock Equity | $-2,855,663 | $6,590,246 | $22,994 |
| Total Equity Gross Minority Interest | $-2,855,663 | $6,590,246 | $22,994 |
| Stockholders Equity | $-2,855,663 | $6,590,246 | $22,994 |
| Gains Losses Not Affecting Retained Earnings | $213,936 | $45,072 | $47,211 |
| Other Equity Adjustments | $213,936 | $45,072 | $47,211 |
| Retained Earnings | $-10,238,359 | $-1,927,043 | $-515,484 |
| Other | |||
| Ordinary Shares Number | $70,789,261 | $70,095,411 | $70,095,411 |
| Share Issued | $70,789,261 | $70,095,411 | $70,095,411 |
| Tangible Book Value | $-5,465,402 | $3,910,211 | $22,994 |
| Invested Capital | $-2,855,663 | $6,590,246 | $57,313 |
| Working Capital | $8,026,612 | $3,204,822 | $-26,494 |
| Capital Lease Obligations | $6,764 | $22,265 | $13,257 |
| Total Capitalization | $-2,855,663 | $6,590,246 | $22,994 |
| Additional Paid In Capital | $7,161,681 | $8,465,744 | $386,067 |
| Capital Stock | $7,079 | $6,473 | $105,200 |
| Common Stock | $7,079 | $6,473 | $105,200 |
| Long Term Capital Lease Obligation | $0 | $5,684 | $0 |
| Current Deferred Revenue | $30,153 | - | $0 |
| Current Capital Lease Obligation | $6,764 | $16,581 | $13,257 |
| Current Accrued Expenses | $403,445 | $182,360 | $13,102 |
| Dueto Related Parties Current | $785,665 | $37,253 | $217,251 |
| Net PPE | $67,810 | $88,077 | $14,305 |
| Accumulated Depreciation | $-28,576 | $-17,431 | $-7,949 |
| Gross PPE | $96,386 | $105,508 | $22,254 |
| Machinery Furniture Equipment | $87,916 | $81,810 | $9,139 |
| Buildings And Improvements | $8,470 | $23,698 | $13,115 |
| Properties | $0 | $0 | $0 |
| Finished Goods | $1,879,542 | $37,335 | $69,404 |
| Duefrom Related Parties Current | $291,540 | $16,927 | $0 |
| Investments And Advances | - | $0 | $10,618 |
| Available For Sale Securities | - | - | $10,618 |
Fetched: 2026-10-21
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Free Cash Flow | |||
| Free Cash Flow | $-8,036,725 | $-4,133,675 | $-55,947 |
| Operating Activities | |||
| Operating Cash Flow | $-6,596,706 | $-1,222,681 | $-55,657 |
| Cash Flow From Continuing Operating Activities | $-6,596,706 | $-1,222,681 | $-55,657 |
| Operating Gains Losses | $3,168,200 | - | $466 |
| Investing Activities | |||
| Capital Expenditure | $-1,440,019 | $-2,910,994 | $-290 |
| Investing Cash Flow | $-1,440,019 | $-2,900,670 | $-290 |
| Cash Flow From Continuing Investing Activities | $-1,440,019 | $-2,900,670 | $-290 |
| Financing Activities | |||
| Issuance Of Capital Stock | $13,200,000 | $7,860,181 | $52,952 |
| Financing Cash Flow | $10,869,150 | $7,113,509 | $113,887 |
| Cash Flow From Continuing Financing Activities | $10,869,150 | $7,113,509 | $113,887 |
| Net Other Financing Charges | $-3,046,495 | $-713,695 | $93,544 |
| Net Common Stock Issuance | $13,200,000 | $7,860,181 | $52,952 |
| Common Stock Issuance | $13,200,000 | $7,860,181 | $52,952 |
| Other | |||
| Repayment Of Debt | $0 | $-32,977 | $-32,609 |
| Interest Paid Supplemental Data | $0 | $772 | $2,144 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 |
| End Cash Position | $6,007,615 | $3,132,298 | $87,098 |
| Beginning Cash Position | $3,132,298 | $87,098 | $30,142 |
| Effect Of Exchange Rate Changes | $42,892 | $55,042 | $-984 |
| Changes In Cash | $2,832,425 | $2,990,158 | $57,940 |
| Proceeds From Stock Option Exercised | $715,645 | $0 | $0 |
| Net Issuance Payments Of Debt | $0 | $-32,977 | $-32,609 |
| Net Long Term Debt Issuance | $0 | $-32,977 | $-32,609 |
| Long Term Debt Payments | $0 | $-32,977 | $-32,609 |
| Net Investment Purchase And Sale | $0 | $10,324 | $0 |
| Sale Of Investment | $0 | $10,324 | $0 |
| Net Intangibles Purchase And Sale | $0 | $-2,836,080 | $0 |
| Purchase Of Intangibles | $0 | $-2,836,080 | $0 |
| Net PPE Purchase And Sale | $-1,440,019 | $-74,914 | $-290 |
| Purchase Of PPE | $-1,440,019 | $-74,914 | $-290 |
| Change In Working Capital | $-1,685,561 | $46,329 | $-126,696 |
| Change In Other Current Liabilities | $-20,744 | $-12,239 | $-47,082 |
| Change In Payables And Accrued Expense | $1,386,562 | $223,791 | $9,996 |
| Change In Accrued Expense | $1,000,138 | $213,595 | $4,605 |
| Change In Payable | $386,424 | $10,196 | $5,391 |
| Change In Account Payable | $386,424 | $10,196 | $5,391 |
| Change In Prepaid Assets | $-850,261 | $-182,721 | $4,818 |
| Change In Inventory | $-1,842,207 | $28,517 | $-30,570 |
| Change In Receivables | $-358,911 | $-11,019 | $-63,858 |
| Changes In Account Receivables | $-84,298 | $6,297 | $-63,858 |
| Other Non Cash Items | $20,471 | $11,731 | $47,740 |
| Asset Impairment Charge | $3,403 | $-493 | $2,731 |
| Deferred Tax | $-1,463 | $26,576 | $4,090 |
| Deferred Income Tax | $-1,463 | $26,576 | $4,090 |
| Depreciation Amortization Depletion | $209,560 | $104,735 | $2,452 |
| Depreciation And Amortization | $209,560 | $104,735 | $2,452 |
| Amortization Cash Flow | $193,314 | $94,536 | $0 |
| Amortization Of Intangibles | $193,314 | $94,536 | $0 |
| Depreciation | $16,246 | $10,199 | $2,452 |
| Gain Loss On Investment Securities | $3,168,091 | - | - |
| Gain Loss On Sale Of PPE | $109 | $0 | $466 |
| Net Income From Continuing Operations | $-8,311,316 | $-1,411,559 | $13,560 |
| Change In Other Working Capital | - | $-614,137 | - |
Fetched: 2026-10-21